FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W155010708> ?p ?o ?g. }

• W155010708 endingPage "35" @default.
• W155010708 startingPage "128" @default.
• W155010708 abstract "The aim of present study was to investigate the feasibility of a densified sequence of FEC75 (5-fluorouracil 600 mg/m2, epirubicin 75 mg/m2, cyclophosphamide 600 mg/m2) and docetaxel 100 mg/m2 (D100) in patients with primary operable high-risk breast cancer.Fifty-one consecutive patients with resectable breast cancer and 4 or more positive axillary lymph nodes were enrolled. After a common regimen of 4 cycles of FEC75 given every 14 days, patients received 4 cycles of D100 every 14 days. Prophylactic granulocyte colony-stimulating factor was administered subcutaneously at 5 mg/kg daily from days 5 to 10 to each patient.The primary endpoint was the proportion of subjects receiving at least 85% of the relative dose intensity (rDI) both in the FEC and docetaxel parts of the regimen. In view of the high percentage of grade 3-4 skin toxicity (32%) observed in the first 25 patients (Group A) during D100 treatment, it was decided to continue the study using a docetaxel dose reduced by 15% (85 mg/m2; D85). This second group of 26 patients was defined as Group B. Of the total 51 patients, 38 (75%) received docetaxel rDI ≥85%, 23/26 patients (88.5%) and 15/25 patients (60.0%) in Group B and Group A, respectively. The observed grade 3-4 hematological and nonhematological toxicities were in line with data from the literature. The only significant difference was the higher percentage of grade 3-4 skin toxicity experienced with D100.This study failed to demonstrate the feasibility of a dose-dense FEC-D regimen with docetaxel 100 mg/m2. Docetaxel 85 mg/m2 seems to allow a higher rDI than docetaxel 100 mg/m2 but this should be confirmed in a larger cohort of patients." @default.
• W155010708 created "2016-06-24" @default.
• W155010708 creator A5016226764 @default.
• W155010708 creator A5019007466 @default.
• W155010708 creator A5028105124 @default.
• W155010708 creator A5044523483 @default.
• W155010708 creator A5054722601 @default.
• W155010708 creator A5060112940 @default.
• W155010708 creator A5063891717 @default.
• W155010708 creator A5089884124 @default.
• W155010708 date "2014-05-24" @default.
• W155010708 modified "2023-09-24" @default.
• W155010708 title "Sequential dose-dense 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel in patients with early breast cancer with four or more positive lymph nodes." @default.
• W155010708 cites W13341330 @default.
• W155010708 cites W1909650807 @default.
• W155010708 cites W1927722732 @default.
• W155010708 cites W1964092375 @default.
• W155010708 cites W1976277928 @default.
• W155010708 cites W2009189135 @default.
• W155010708 cites W2019694705 @default.
• W155010708 cites W2024131269 @default.
• W155010708 cites W2027906728 @default.
• W155010708 cites W2035163093 @default.
• W155010708 cites W2036067444 @default.
• W155010708 cites W2058680863 @default.
• W155010708 cites W2071231406 @default.
• W155010708 cites W2075213874 @default.
• W155010708 cites W2076709420 @default.
• W155010708 cites W2097996372 @default.
• W155010708 cites W2099562503 @default.
• W155010708 cites W2101760255 @default.
• W155010708 cites W2111666200 @default.
• W155010708 cites W2112217271 @default.
• W155010708 cites W2116780500 @default.
• W155010708 cites W2117239059 @default.
• W155010708 cites W2123528875 @default.
• W155010708 cites W2125835228 @default.
• W155010708 cites W2127232551 @default.
• W155010708 cites W2128941584 @default.
• W155010708 cites W2132893003 @default.
• W155010708 cites W2136802843 @default.
• W155010708 cites W2137191334 @default.
• W155010708 cites W2138718630 @default.
• W155010708 cites W2140654333 @default.
• W155010708 cites W2144418840 @default.
• W155010708 cites W2150706560 @default.
• W155010708 cites W2154864146 @default.
• W155010708 cites W2164409215 @default.
• W155010708 cites W2166572860 @default.
• W155010708 cites W2167779518 @default.
• W155010708 cites W2247641735 @default.
• W155010708 cites W3010963564 @default.
• W155010708 doi "https://doi.org/10.1700/1491.16393" @default.
• W155010708 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24852855" @default.
• W155010708 hasPublicationYear "2014" @default.
• W155010708 type Work @default.
• W155010708 sameAs 155010708 @default.
• W155010708 citedByCount "1" @default.
• W155010708 countsByYear W1550107082021 @default.
• W155010708 crossrefType "journal-article" @default.
• W155010708 hasAuthorship W155010708A5016226764 @default.
• W155010708 hasAuthorship W155010708A5019007466 @default.
• W155010708 hasAuthorship W155010708A5028105124 @default.
• W155010708 hasAuthorship W155010708A5044523483 @default.
• W155010708 hasAuthorship W155010708A5054722601 @default.
• W155010708 hasAuthorship W155010708A5060112940 @default.
• W155010708 hasAuthorship W155010708A5063891717 @default.
• W155010708 hasAuthorship W155010708A5089884124 @default.
• W155010708 hasConcept C121608353 @default.
• W155010708 hasConcept C126322002 @default.
• W155010708 hasConcept C126894567 @default.
• W155010708 hasConcept C141071460 @default.
• W155010708 hasConcept C143998085 @default.
• W155010708 hasConcept C168563851 @default.
• W155010708 hasConcept C203092338 @default.
• W155010708 hasConcept C2776694085 @default.
• W155010708 hasConcept C2776755627 @default.
• W155010708 hasConcept C2778496288 @default.
• W155010708 hasConcept C2780456651 @default.
• W155010708 hasConcept C2780835546 @default.
• W155010708 hasConcept C2781190966 @default.
• W155010708 hasConcept C2781413609 @default.
• W155010708 hasConcept C29730261 @default.
• W155010708 hasConcept C530470458 @default.
• W155010708 hasConcept C71924100 @default.
• W155010708 hasConcept C90924648 @default.
• W155010708 hasConceptScore W155010708C121608353 @default.
• W155010708 hasConceptScore W155010708C126322002 @default.
• W155010708 hasConceptScore W155010708C126894567 @default.
• W155010708 hasConceptScore W155010708C141071460 @default.
• W155010708 hasConceptScore W155010708C143998085 @default.
• W155010708 hasConceptScore W155010708C168563851 @default.
• W155010708 hasConceptScore W155010708C203092338 @default.
• W155010708 hasConceptScore W155010708C2776694085 @default.
• W155010708 hasConceptScore W155010708C2776755627 @default.
• W155010708 hasConceptScore W155010708C2778496288 @default.
• W155010708 hasConceptScore W155010708C2780456651 @default.
• W155010708 hasConceptScore W155010708C2780835546 @default.

• next